Pfizer to buy rest of Biohaven for $11.6B

Pfizer Inc. agreed to buy the rest of Biohaven Pharmaceutical Holding Co. for about $11.6 billion, deploying its pile of cash earned from Covid-19 sales to acquire a new migraine drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.